Eric Nuermberger

PROFESSOR

19992019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1999 2019

2019

Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection

Kaushik, A., Ammerman, N., Tyagi, S., Saini, V., Vervoort, I., Lachau-Durand, S., Nuermberger, E. & Andries, K., Apr 1 2019, In : Antimicrobial agents and chemotherapy. e00007-19.

Research output: Contribution to journalArticle

Open Access
bedaquiline
Latent Tuberculosis
Injections
rifapentine
Lung

Advancing translational science for pulmonary nontuberculous mycobacterial infections: A road map for research

Daniel-Wayman, S., Abate, G., Barber, D. L., Bermudez, L. E., Coler, R. N., Cynamon, M. H., Daley, C. L., Davidson, R. M., Dick, T., Floto, R. A., Henkle, E., Holland, S. M., Jackson, M., Lee, R. E., Nuermberger, E., Olivier, K. N., Ordway, D. J., Prevots, D. R., Sacchettini, J. C., Salfinger, M. & 4 othersSassetti, C. M., Sizemore, C. F., Winthrop, K. L. & Zelazny, A. M., Apr 15 2019, In : American journal of respiratory and critical care medicine. 199, 8, p. 947-951 5 p.

Research output: Contribution to journalReview article

Lung
Infection
Research

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

Xu, J., Li, S. Y., Almeida, D. V., Tasneen, R., Barnes-Boyle, K., Converse, P. J., Upton, A. M., Mdluli, K., Fotouhi, N. & Nuermberger, E., May 1 2019, In : Antimicrobial agents and chemotherapy. 63, 5, e00021-19.

Research output: Contribution to journalArticle

Open Access
Linezolid
bedaquiline
Pyrazinamide
Tuberculosis
Nude Mice

Dual β-lactam combinations highly active against mycobacterium abscessus complex in vitro

Pandey, R., Chen, L., Manca, C., Jenkins, S., Glaser, L., Vinnard, C., Stone, G., Lee, J., Mathema, B., Nuermberger, E., Bonomo, R. A. & Kreiswirth, B. N., Jan 1 2019, In : mBio. 10, 1, e02895-18.

Research output: Contribution to journalArticle

Open Access
Lactams
Ceftazidime
Mycobacterium
Imipenem
Anti-Bacterial Agents

High-dose rifamycins enable shorter oral treatment in a murine model of mycobacterium ulcerans disease

Omansen, T. F., Almeida, D., Converse, P. J., Li, S. Y., Lee, J., Stienstra, Y., van der Werf, T., Grosset, J. H. & Nuermberger, E., Feb 1 2019, In : Antimicrobial Agents and Chemotherapy. 63, 2, e01478-18.

Research output: Contribution to journalArticle

rifapentine
Rifamycins
Mycobacterium ulcerans
Rifampin
Buruli Ulcer
Mycobacterium
Tetracycline
Pharmaceutical Preparations
Salvage Therapy
Mycobacterium Infections
Lactams
Mycobacterium
meropenem
Cefuroxime
Carbapenems

One month of rifapentine plus isoniazid to prevent HIV-related Tuberculosis

BRIEF TB/A5279 Study Team, Mar 14 2019, In : New England Journal of Medicine. 380, 11, p. 1001-1011 11 p.

Research output: Contribution to journalArticle

rifapentine
Isoniazid
Tuberculosis
HIV
Confidence Intervals

Oxazolidinones can replace clarithromycin in combination with rifampin in a mouse model of Buruli ulcer

Almeida, D. V., Omansen, T. F., Li, S. Y., Lee, J., Grosset, J. H., Converse, P. J. & Nuermberger, E., Mar 1 2019, In : Antimicrobial agents and chemotherapy. e02171-18.

Research output: Contribution to journalArticle

Buruli Ulcer
Linezolid
Oxazolidinones
Clarithromycin
Rifampin
rifapentine
Clofazimine
Tuberculosis
Rifampin
Therapeutics

Understanding the significance of biochemistry in the storage, handling, purification, and sampling of amphiphilic mycolactone

Kubicek-Sutherland, J. Z., Vu, D. M., Anderson, A. S., Sanchez, T. C., Converse, P. J., Martí-Arbona, R., Nuermberger, E., Swanson, B. I. & Mukundan, H., Apr 1 2019, In : Toxins. 11, 4, 202.

Research output: Contribution to journalArticle

Open Access
Biochemistry
Purification
Sampling
Buruli Ulcer
Mycobacterium ulcerans
2018

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

Leung-Theung-Long, S., Coupet, C. A., Gouanvic, M., Schmitt, D., Ray, A., Hoffmann, C., Schultz, H., Tyagi, S., Soni, H., Converse, P. J., Arias, L., Kleinpeter, P., Sansas, B., Mdluli, K., Vilaplana, C., Cardona, P. J., Nuermberger, E., Marchand, J. B., Silvestre, N. & Inchauspé, G., May 1 2018, In : PLoS One. 13, 5, e0196815.

Research output: Contribution to journalArticle

Vaccinia
Chemotherapy
Vaccinium
Mycobacterium tuberculosis
Combination Drug Therapy

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis

Ammerman, N., Swanson, R. V., Bautista, E. M., Almeida, D. V., Saini, V., Omansen, T. F., Guo, H., Chang, Y. S., Li, S. Y., Tapley, A., Tasneen, R., Tyagi, S., Betoudji, F., Moodley, C., Ngcobo, B., Pillay, L., Bester, L. A., Singh, S. D., Chaisson, R. E., Nuermberger, E. & 1 othersGrosset, J. H., Jul 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 7, e00636-18.

Research output: Contribution to journalArticle

Clofazimine
Tuberculosis
Pharmaceutical Preparations
Therapeutics
Multidrug-Resistant Tuberculosis

Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges

Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., Nuermberger, E., Kim, P., Barry, C. E., Owen, A., Hazuda, D. & Flexner, C. W., Feb 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 2, p. 125-132 8 p.

Research output: Contribution to journalReview article

Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis

Deshpande, D., Srivastava, S., Nuermberger, E., Koeuth, T., Martin, K. R., Cirrincione, K. N., Lee, P. S. & Gumbo, T., Nov 28 2018, In : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 67, 3, p. S342-S348

Research output: Contribution to journalArticle

Linezolid
Tuberculosis
Mitochondrial Genes
Stem Cells
Therapeutics

New drugs and regimens for tuberculosis

Chang, K. C., Nuermberger, E., Sotgiu, G. & Leung, C. C., Nov 1 2018, In : Respirology. 23, 11, p. 978-990 13 p.

Research output: Contribution to journalReview article

Multidrug-Resistant Tuberculosis
Drug Repositioning
Tuberculosis
Drug Resistance
Pharmaceutical Preparations

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

Converse, P. J., Almeida, D. V., Tasneen, R., Saini, V., Tyagi, S., Ammerman, N., Li, S. Y., Anders, N., Rudek-Renaut, M., Grosset, J. H. & Nuermberger, E., Aug 1 2018, In : PLoS Neglected Tropical Diseases. 12, 8, e0006728.

Research output: Contribution to journalArticle

Rifamycins
Mycobacterium ulcerans
Buruli Ulcer
Clofazimine
Rifampin

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis

Srivastava, S., Deshpande, D., Nuermberger, E., Lee, P. S., Cirrincione, K., Dheda, K. & Gumbo, T., Nov 28 2018, In : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 67, 3, p. S336-S341

Research output: Contribution to journalArticle

Linezolid
Pulmonary Tuberculosis
Microbial Sensitivity Tests
Tuberculosis
Stem Cells

Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis

Xu, J., Tasneen, R., Peloquin, C. A., Almeida, D. V., Li, S. Y., Barnes-Boyle, K., Lu, Y. & Nuermberger, E., Jan 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 1, e01692.

Research output: Contribution to journalArticle

bedaquiline
Clofazimine
Verapamil
Biological Availability
Tuberculosis
2017

Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Li, S. Y., Tasneen, R., Tyagi, S., Soni, H., Converse, P. J., Mdluli, K. & Nuermberger, E., Sep 1 2017, In : Antimicrobial Agents and Chemotherapy. 61, 9, e00913-17.

Research output: Contribution to journalArticle

bedaquiline
Pyrazinamide
Tuberculosis
Drug Combinations
Recurrence

Delamanid and pretomanid

Nuermberger, E. & Kendall, E., Jan 1 2017, Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, p. 2550-2558 9 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Multidrug-Resistant Tuberculosis
Japan
Tuberculosis
Pharmaceutical Preparations
OPC-67683

Drug resistance mechanisms and novel drug targets for tuberculosis therapy

Islam, M. M., Hameed, H. M. A., Mugweru, J., Chhotaray, C., Wang, C., Tan, Y., Liu, J., Li, X., Tan, S., Ojima, I., Yew, W. W., Nuermberger, E., Lamichhane, G. & Zhang, T., Jan 20 2017, In : Journal of Genetics and Genomics. 44, 1, p. 21-37 17 p.

Research output: Contribution to journalReview article

Drug Resistance
Tuberculosis
Pharmaceutical Preparations
Multidrug-Resistant Tuberculosis
Therapeutics

Immunodeficiency and intermittent dosing promote acquired rifamycin monoresistance in murine tuberculosis

Park, S. W., Tasneen, R., Converse, P. J. & Nuermberger, E., Nov 1 2017, In : Antimicrobial Agents and Chemotherapy. 61, 11, e01502-17.

Research output: Contribution to journalArticle

rifapentine
Isoniazid
Tuberculosis
Rifampin
Nude Mice

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis

Kaushik, A., Ammerman, N., Tasneen, R., Story-Roller, E., Dooley, K. E., Dorman, S. E., Nuermberger, E. & Lamichhane, G., Aug 1 2017, In : Journal of Antimicrobial Chemotherapy. 72, 8, p. 2320-2325 6 p., dkx152.

Research output: Contribution to journalArticle

biapenem
Rifampin
Mycobacterium tuberculosis
Pharmaceutical Preparations
In Vitro Techniques

In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1

Gopal, P., Tasneen, R., Yee, M., Lanoix, J. P., Sarathy, J., Rasic, G., Li, L., Dartois, V., Nuermberger, E. & Dick, T., Jul 14 2017, In : ACS Infectious Diseases. 3, 7, p. 492-501 10 p.

Research output: Contribution to journalArticle

aspartate 4-decarboxylase
Missense Mutation
Pyrazinamide
Mycobacterium tuberculosis
Mutation

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response

Bartelink, I. H., Zhang, N., Keizer, R. J., Strydom, N., Converse, P. J., Dooley, K. E., Nuermberger, E. & Savic, R. M., 2017, (Accepted/In press) In : Clinical and Translational Science.

Research output: Contribution to journalArticle

Tuberculosis
rifapentine
Pharmacokinetics
Confidence Intervals
Rifampin

Preclinical Efficacy Testing of New Drug Candidates

Nuermberger, E., Jun 1 2017, In : Microbiology spectrum. 5, 3

Research output: Contribution to journalReview article

chemotherapy
drug
Latent Tuberculosis
Drug Therapy
Drug Combinations

Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis

Xu, J., Wang, B., Hu, M., Huo, F., Guo, S., Jing, W., Nuermberger, E. & Lu, Y., Jun 1 2017, In : Antimicrobial Agents and Chemotherapy. 61, 6, e00239-17.

Research output: Contribution to journalArticle

bedaquiline
Clofazimine
Multidrug-Resistant Tuberculosis
Mutation
Extensively Drug-Resistant Tuberculosis

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model

Kendall, E., Shrestha, S., Cohen, T., Nuermberger, E., Dooley, K. E., Gonzalez-Angulo, L., Churchyard, G. J., Nahid, P., Rich, M. L., Bansbach, C., Forissier, T., Lienhardt, C. & Dowdy, D. W., Jan 1 2017, In : PLoS Medicine. 14, 1, e1002202.

Research output: Contribution to journalArticle

Rifampin
Tuberculosis
Uncertainty
Pharmaceutical Preparations
Mortality

Pyrazinoic acid inhibits a bifunctional enzyme in Mycobacterium tuberculosis

Njire, M., Wang, N., Wang, B., Tan, Y., Cai, X., Liu, Y., Mugweru, J., Guo, J., Hameed, H. M. A., Tan, S., Liu, J., Yew, W. W., Nuermberger, E., Lamichhane, G., Liu, J. & Zhang, T., Jul 1 2017, In : Antimicrobial Agents and Chemotherapy. 61, 7, e00070-17.

Research output: Contribution to journalArticle

Pyrazinamide
Mycobacterium tuberculosis
Enzymes
Alleles
Pharmaceutical Preparations

Sutezolid

Salazar-Austin, N. & Nuermberger, E., Jan 1 2017, Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, p. 2559-2563 5 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Linezolid
Oxazolidinones
Bacterial Proteins
Anti-Infective Agents
Sulfur

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., Theron, G., van Helden, P., Niemann, S., Merker, M., Dowdy, D. W., Van Rie, A., Siu, G. K. H., Pasipanodya, J. G., Rodrigues, C., Clark, T. G. & 22 othersSirgel, F. A., Esmail, A., Lin, H. H., Atre, S. R., Schaaf, H. S., Chang, K. C., Lange, C., Nahid, P., Udwadia, Z. F., Horsburgh, C. R., Churchyard, G. J., Menzies, D., Hesseling, A. C., Nuermberger, E., McIlleron, H., Fennelly, K. P., Goemaere, E., Jaramillo, E., Low, M., Jara, C. M., Padayatchi, N. & Warren, R. M., Apr 1 2017, In : The Lancet Respiratory Medicine. 5, 4, p. 291-360 70 p.

Research output: Contribution to journalReview article

Extensively Drug-Resistant Tuberculosis
Epidemiology
Tuberculosis
Multidrug-Resistant Tuberculosis
Linezolid
2016

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

Srivastava, S., Deshpande, D., Pasipanodya, J. G., Thomas, T., Swaminathan, S., Nuermberger, E. & Gumbo, T., Nov 1 2016, In : Clinical Infectious Diseases. 63, p. S75-S79

Research output: Contribution to journalArticle

Tuberculosis
Pharmaceutical Preparations
Drug Combinations
Pharmacokinetics
Clinical Trials

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

Deshpande, D., Srivastava, S., Nuermberger, E., Pasipanodya, J. G., Swaminathan, S. & Gumbo, T., Nov 1 2016, In : Clinical Infectious Diseases. 63, p. S95-S101

Research output: Contribution to journalArticle

Linezolid
Multidrug-Resistant Tuberculosis
Pharmaceutical Preparations
Stem Cells
Pediatrics

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice

Irwin, S. M., Prideaux, B., Lyon, E. R., Zimmerman, M. D., Brooks, E. J., Schrupp, C. A., Chen, C., Reichlen, M. J., Asay, B. C., Voskuil, M. I., Nuermberger, E., Andries, K., Lyons, M. A., Dartois, V. & Lenaerts, A. J., Apr 8 2016, In : ACS Infectious Diseases. 2, 4, p. 251-267 17 p.

Research output: Contribution to journalArticle

bedaquiline
Pyrazinamide
Mycobacterium tuberculosis
Lung
Granuloma

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

Deshpande, D., Srivastava, S., Nuermberger, E., Pasipanodya, J. G., Swaminathan, S. & Gumbo, T., Nov 1 2016, In : Clinical Infectious Diseases. 63, p. S88-S94

Research output: Contribution to journalArticle

Linezolid
Tuberculosis
Mycobacterium tuberculosis
Therapeutics
Appointments and Schedules

Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis

Tasneen, R., Betoudji, F., Tyagi, S., Li, S. Y., Williams, K., Converse, P. J., Dartois, V., Yang, T., Mendel, C. M., Mdluli, K. E. & Nuermberger, E., Jan 1 2016, In : Antimicrobial Agents and Chemotherapy. 60, 1, p. 270-277 8 p.

Research output: Contribution to journalArticle

bedaquiline
Linezolid
Oxazolidinones
Tuberculosis
Pyrazinamide

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children with Tuberculosis: Bread Crumb Trails in Random Forests

Swaminathan, S., Pasipanodya, J. G., Ramachandran, G., Kumar, A. K. H., Srivastava, S., Deshpande, D., Nuermberger, E. & Gumbo, T., Nov 1 2016, In : Clinical Infectious Diseases. 63, p. S63-S74

Research output: Contribution to journalArticle

Bread
Tuberculosis
Rifampin
Pyrazinamide
Pharmaceutical Preparations
Linezolid
Tuberculosis
Multidrug-Resistant Tuberculosis
Mitochondrial Proteins
Pharmaceutical Preparations

High systemic exposure of pyrazinoic acid has limited antituberculosis activity in murine and rabbit models of tuberculosis

Lanoix, J. P., Tasneen, R., O'Brien, P., Sarathy, J., Safi, H., Pinn, M., Alland, D., Dartois, V. & Nuermberger, E., Jul 1 2016, In : Antimicrobial Agents and Chemotherapy. 60, 7, p. 4197-4205 9 p.

Research output: Contribution to journalArticle

Pyrazinamide
Tuberculosis
Rabbits
pyrazinoic acid
amidase

Linezolid for Infants and Toddlers with Disseminated Tuberculosis: First Steps

Deshpande, D., Srivastava, S., Pasipanodya, J. G., Bush, S. J., Nuermberger, E., Swaminathan, S. & Gumbo, T., Nov 1 2016, In : Clinical Infectious Diseases. 63, p. S80-S87

Research output: Contribution to journalArticle

Linezolid
Tuberculosis
Mycobacterium tuberculosis
Microbial Sensitivity Tests
Half-Life

Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9

Ordonez Suarez, A., Tasneen, R., Pokkali, S., Xu, Z., Converse, P. J., Klunk, M. H., Mollura, D. J., Nuermberger, E. & Jain, S., Jul 1 2016, In : DMM Disease Models and Mechanisms. 9, 7, p. 779-788 10 p.

Research output: Contribution to journalArticle

Matrix Metalloproteinase 9
Pulmonary Tuberculosis
Cavitation
Tuberculosis
Matrix Metalloproteinases

Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis

Almeida, D., Ioerger, T., Tyagi, S., Li, S. Y., Mdluli, K., Andries, K., Grosset, J., Sacchettini, J. & Nuermberger, E., Aug 1 2016, In : Antimicrobial Agents and Chemotherapy. 60, 8, p. 4590-4599 10 p.

Research output: Contribution to journalArticle

bedaquiline
Clofazimine
Mycobacterium tuberculosis
Mutation
Multidrug-Resistant Tuberculosis

MYCOBACT-18 - Qualification des souris C3HeB/FeJ pour le traitement expérimental de la tuberculose

Lanoix, J. P., Schmit, J. L. & Nuermberger, E., Jun 1 2016, In : Medecine et Maladies Infectieuses. 46, 4, p. 84 1 p.

Research output: Contribution to journalArticle

Tuberculosis

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children with Disseminated Tuberculosis: Goldilocks

Srivastava, S., Deshpande, D., Pasipanodya, J., Nuermberger, E., Swaminathan, S. & Gumbo, T., Nov 1 2016, In : Clinical Infectious Diseases. 63, p. S102-S109

Research output: Contribution to journalArticle

Linezolid
Tuberculosis
Microbial Sensitivity Tests
Pharmaceutical Preparations
Anti-Bacterial Agents

Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum

Lanoix, J. P., Ioerger, T., Ormond, A., Kaya, F., Sacchettini, J., Dartois, V. & Nuermberger, E., Feb 1 2016, In : Antimicrobial Agents and Chemotherapy. 60, 2, p. 735-743 9 p.

Research output: Contribution to journalArticle

Pyrazinamide
Tuberculosis
Lung
Pharmaceutical Preparations
Bacillus

Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis

Lanoix, J. P., Betoudji, F. & Nuermberger, E., Feb 1 2016, In : Antimicrobial Agents and Chemotherapy. 60, 2, p. 1091-1096 6 p.

Research output: Contribution to journalArticle

Pyrazinamide
Tuberculosis
Pharmaceutical Preparations
Recurrence
Ethambutol
National Institute of Allergy and Infectious Diseases (U.S.)
Critical Pathways
Tuberculosis
Pharmacology
Education
2015

A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections

Locher, C. P., Jones, S. M., Hanzelka, B. L., Perola, E., Shoen, C. M., Cynamon, M. H., Ngwane, A. H., Wiid, I. J., Van Helden, P. D., Betoudji, F., Nuermberger, E. & Thomson, J. A., Mar 1 2015, In : Antimicrobial Agents and Chemotherapy. 59, 3, p. 1455-1465 11 p.

Research output: Contribution to journalArticle

Tuberculosis
Prodrugs
Infection
Pharmaceutical Preparations
Mycobacterium tuberculosis

Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen Development

Nuermberger, E. & Hanna, D., Jun 15 2015, In : Journal of Infectious Diseases. 211, p. S81-S82

Research output: Contribution to journalArticle

Antitubercular Agents
Multidrug-Resistant Tuberculosis
Tuberculosis
Animal Models
Pharmacokinetics